BC
RARE icon

Birchview Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

Birchview Capital’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.3M Hold
62,000
– – 0.74% 36
2025
Q4 		$1.43M Buy
62,000
+40,000
+182% +$1.32M 0.83% 32
2025
Q3 		$662K Buy
22,000
+4,000
+22% +$120K 0.5% 45
2025
Q2 		$654K Buy
18,000
+2,000
+13% +$72.1K 0.65% 35
2025
Q1 		$579K Hold
16,000
– – 0.5% 30
2024
Q4 		$673K Buy
+16,000
New +$794K 0.55% 26

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Birchview Capital's RARE Position: Q1 2026 in Review

Birchview Capital held its Ultragenyx Pharmaceutical (RARE) position steady in Q1 2026 at 62,000 shares worth $1.3M. The position accounts for 0.74% of the portfolio, ranked #36.

Birchview Capital first reported a position in RARE in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.43M in Q4 2025. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Birchview Capital held 62,000 shares of Ultragenyx Pharmaceutical worth $1.3M as of Q1 2026.
  • Birchview Capital left its Ultragenyx Pharmaceutical share count unchanged in Q1 2026.
  • Ultragenyx Pharmaceutical made up 0.74% of Birchview Capital's portfolio in Q1 2026, its #36 holding.
  • Birchview Capital first reported a position in Ultragenyx Pharmaceutical in Q4 2024 and has held it in 6 quarters since.
  • Birchview Capital's Ultragenyx Pharmaceutical position peaked at $1.43M in Q4 2025.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Birchview Capital's 13F filing for Q1 2026, filed 15 May 2026.